Cargando…

Prognostic Value of Thyroid Hormone Ratio in Patients With Advanced Metastatic Renal Cell Carcinoma: Results From the Threefour Study (Meet-URO 14)

BACKGROUND: Thyroid hormone impairment, represented as an alteration in levels of thyroid hormones and a lower fT3/fT4 ratio, has been correlated with a worse prognosis for both cancer and non-cancer patients. The role of baseline thyroid function in patients with metastatic renal cell carcinoma (mR...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maruzzo, Marco, Verzoni, Elena, Vitale, Maria Giuseppa, Dionese, Michele, Buti, Sebastiano, Galli, Luca, Zivi, Andrea, Watutantrige-Fernando, Sara, Zielli, Teresa, Zanardi, Elisa, Sabbatini, Roberto, Basso, Umberto, Zagonel, Vittorina, Procopio, Giuseppe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8655227/ https://www.ncbi.nlm.nih.gov/pubmed/34900742 http://dx.doi.org/10.3389/fonc.2021.787835

Ejemplares similares

Nivolumab drug holiday in patients treated for metastatic renal cell carcinoma: A real-world, single-centre experience
por: Bimbatti, Davide, et al.
Publicado: (2022)

Patient Reported Outcomes, Paternity, Relationship, and Fertility in Testicular Cancer Survivors: Results from a Prospective Observational Single Institution Trial
por: Bimbatti, Davide, et al.
Publicado: (2022)

Impact of Previous Nephrectomy on Clinical Outcome of Metastatic Renal Carcinoma Treated With Immune-Oncology: A Real-World Study on Behalf of Meet-URO Group (MeetUro-7b)
por: Stellato, Marco, et al.
Publicado: (2021)

Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib
por: Rebuzzi, Sara Elena, et al.
Publicado: (2022)

Tumour Seeding After a Thoracic Biopsy for Renal Cell Carcinoma: A Case Report and a Review of the Literature
por: Michele, Dionese, et al.
Publicado: (2021)

Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a)
por: Stellato, Marco, et al.
Publicado: (2023)

Neoadjuvant sirolimus for a large hepatic perivascular epithelioid cell tumor (PEComa)
por: Bergamo, Francesca, et al.
Publicado: (2014)

Editorial: The ever-changing scenario of first line treatment of metastatic renal cell carcinoma
por: Vitale, Maria Giuseppa, et al.
Publicado: (2023)

Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study)
por: Bersanelli, Melissa, et al.
Publicado: (2021)

Trabectedin Drug Holiday and Rechallenge in Soft Tissue Sarcomas: Report of 4 Cases and Literature Review
por: Pierantoni, Francesco, et al.
Publicado: (2019)

Prognostic Stratification of Metastatic Prostate Cancer Patients Treated With Abiraterone and Enzalutamide Through an Integrated Analysis of Circulating Free microRNAs and Clinical Parameters
por: Sharova, Evgeniya, et al.
Publicado: (2021)

Clinical outcome of renal cancer patients who early interrupted immunotherapy due to serious immune-related adverse events. Meet-Uro 13 trial on behalf of the MeetUro investigators
por: Stellato, Marco, et al.
Publicado: (2021)

Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet‐Uro 19BEYOND study
por: Roviello, Giandomenico, et al.
Publicado: (2022)

Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program
por: Rebuzzi, S.E., et al.
Publicado: (2022)

The Geriatric G8 Score Is Associated with Survival Outcomes in Older Patients with Advanced Prostate Cancer in the ADHERE Prospective Study of the Meet-URO Network
por: Banna, Giuseppe Luigi, et al.
Publicado: (2022)

The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal cell carcinoma treated with nivolumab: The Δ-Meet-URO analysis
por: Rebuzzi, Sara Elena, et al.
Publicado: (2022)

The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study
por: Rebuzzi, Sara Elena, et al.
Publicado: (2022)

BONSAI-2 study: Nivolumab as therapeutic option after cabozantinib failure in metastatic collecting duct carcinoma patients
por: Buti, Sebastiano, et al.
Publicado: (2022)

Adjuvant chemotherapy for soft tissue sarcomas: a 10-year mono-institutional experience
por: Brunello, Antonella, et al.
Publicado: (2015)

A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03)
por: Procopio, Giuseppe, et al.
Publicado: (2022)

Real-World Treatment with Nivolumab or Cabozantinib for Metastatic Renal Cell Carcinoma (mRCC) in the Veneto Region of Italy: Results of AMOUR Study
por: Maruzzo, Marco, et al.
Publicado: (2022)

Prognostic role of systemic inflammation indexes in metastatic urothelial carcinoma treated with immunotherapy
por: Dionese, Michele, et al.
Publicado: (2023)

Response to trabectedin in a patient with advanced synovial sarcoma with lung metastases
por: Zanardi, Elisa, et al.
Publicado: (2014)

Nefro-Uro /
Publicado: (2018)

Renal cell carcinoma: the population, real world, and cost-of-illness
por: Buja, Alessandra, et al.
Publicado: (2022)

Characterization of Tumor and Immune Tumor Microenvironment of Primary Tumors and Metastatic Sites in Advanced Renal Cell Carcinoma Patients Based on Response to Nivolumab Immunotherapy: Preliminary Results from the Meet-URO 18 Study
por: Rebuzzi, Sara Elena, et al.
Publicado: (2023)

Essentials of Uro-Radiology
por: Kabala, J. E.
Publicado: (1991)

Haema-Uro-Chrome
Publicado: (1914)

Long-Term Response to Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma
por: Catalano, Martina, et al.
Publicado: (2022)

Adherence to Oral Treatments in Older Patients with Advanced Prostate Cancer, the ADHERE Study: A Prospective Trial of the Meet-URO Network
por: Rescigno, Pasquale, et al.
Publicado: (2022)

Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study
por: Brunelli, Matteo, et al.
Publicado: (2022)

Robotics in uro-oncologic surgery
por: De Lorenzis, Elisa, et al.
Publicado: (2013)

Caring for Patients with Advanced Stage Cancer at the Time of COVID‐19
por: Brunello, Antonella, et al.
Publicado: (2020)

Positron emission tomography in uro-oncology
por: Hain, S F
Publicado: (2005)

Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study)
por: Rebuzzi, Sara Elena, et al.
Publicado: (2021)

To Transplant or Not to Transplant During the SARS‐CoV‐2 Pandemic? That Is the Question
por: Marino, Dario, et al.
Publicado: (2020)

Impact of COVID-19 on Uro-Oncological Patients: A Comprehensive Review of the Literature
por: Gavi, Filippo, et al.
Publicado: (2023)

Evaluation of UroVysion for Urachal Carcinoma Detection
por: Hu, Zhiquan, et al.
Publicado: (2020)

Kidney and uro-trauma: WSES-AAST guidelines
por: Coccolini, Federico, et al.
Publicado: (2019)

Renal actinomycosis presenting as uro-cutaneous fistula
por: Diab, Christian, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_fn00d9osc3gcp91mke980dohqo